Latest Conference Coverage


Ilena George, MD

Prescribing DMT in Radiologically Isolated Syndrome: Ilena George, MD

March 7th 2021

The neurologist from Massachusetts General Hospital discussed physician rationales behind prescribing DMT use in RIS.


Understanding the Momentum in the Autoimmune Encephalitis Research Community

Understanding the Momentum in the Autoimmune Encephalitis Research Community

March 5th 2021

The assistant professor of neurology at Mayo Clinic discussed his presented talk at ACTRIMS Forum 2021 on autoimmune encephalitis.


African American Patients With MS Switch to Ocrelizumab Treatment Earlier than Caucasian Patients

African American Patients With MS Switch to Ocrelizumab Treatment Earlier than Caucasian Patients

March 4th 2021

Researchers also found that patients with progressive MS had longer disease duration before starting DMTs than those with relapsing MS.


How COViMS Registry Is Clarifying MS COVID-19 Risks: Amber Salter, MPH, PhD

How COViMS Registry Is Clarifying MS COVID-19 Risks: Amber Salter, MPH, PhD

March 4th 2021

The assistant professor of biostatistics at Washington University in St. Louis discussed what role the COViMS registry can play for the MS community at this stage in the pandemic.


Julia Luo

Human Oligodendrocyte Differences Due to Environmental Signals Rather Than Lineage

March 4th 2021

Researchers used single-cell RNA sequencing on adult, pediatric, and infant surgical tissues to study oligodendrocyte types in order to better understand multiple sclerosis.


Spencer Hutto, MD

High Rates of MS Relapse after TNFα Inhibitor Discontinuation: Spencer Hutto, MD

March 3rd 2021

The fellow of autoimmune neurology at Massachusetts General Hospital discusses the ongoing question about whether the demyelination is an unmasking of disease or consequence of the treatment.


Stephanie Blandford, MSc

Predicting MS Disability With IL-1 Receptor Antagonist Levels: Stephanie Blandford, MSc

March 3rd 2021

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed her team’s investigations into the use of IL-1RA as a biomarker for MS disability.


NeuroVoices: Dylan Rice, on Improving Adherence to MS DMTs

NeuroVoices: Dylan Rice, on Improving Adherence to MS DMTs

March 3rd 2021

The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS 2021 on electronic pill bottle monitoring to promote MS medication adherence.


Expanding Research in Autoimmune Encephalitis: Divyanshu Dubey, MBBS

Expanding Research in Autoimmune Encephalitis: Divyanshu Dubey, MBBS

March 2nd 2021

The assistant professor of neurology at Mayo Clinic provided his thoughts on the next steps in understanding autoimmune encephalitis and the direction that research must pivot to.


Remote Technology Improves Adherence Rates in Relapsing MS

Remote Technology Improves Adherence Rates in Relapsing MS

March 2nd 2021

The authors expanded upon the notion that nonadherence to oral DMTs is more nuanced than simply missing doses.


Stephanie Blandford, MSc, PhD candidate

IL-1RA Biomarker Predicts Disability in Multiple Sclerosis

March 1st 2021

The researchers found that interleukin-1 receptor antagonist levels in plasma correlated with neurofilament light levels in cerebrospinal fluid.


Unmet Needs in the Multiple Sclerosis Community: Luc Truyen, MD, PhD

Unmet Needs in the Multiple Sclerosis Community: Luc Truyen, MD, PhD

March 1st 2021

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed areas of multiple sclerosis research that need more attention.


Prevalence of Autoimmune Encephalitis: Divyanshu Dubey, MBBS

Prevalence of Autoimmune Encephalitis: Divyanshu Dubey, MBBS

February 28th 2021

The assistant professor of neurology at Mayo Clinic detailed his presentation at ACTRIMS 2021 Forum on the rising prevalence of autoimmune encephalitis.


 Ilena George, MD

Increasing Prevalence of Early DMT Prescription in Radiologically Isolated Syndrome

February 27th 2021

Researchers from Massachusetts General Hospital found that DMT-treated patients were, on average, younger than untreated patients.


Fingolimod Shows Potential to Reduce Retinal Neurodegeneration in Relapsing MS

Fingolimod Shows Potential to Reduce Retinal Neurodegeneration in Relapsing MS

February 27th 2021

The authors concluded that longitudinal optical coherence tomography measures may be sensitive to changes in cognitive function and may be useful for monitoring neuroprotective therapies.


Ishu Arpan, PT, PhD

Instrumented Postural Sway Test Differentiates Fallers From Non-Fallers in MS

February 26th 2021

Researchers investigated the test, which is normally used to differentiate people with MS from healthy controls, in a population of those with multiple sclerosis.


Spencer Hutto, MD

Investigating TNFα Inhibition and CNS Demyelination: Spencer Hutto, MD

February 26th 2021

The fellow of autoimmune neurology at Massachusetts General Hospital discussed the analysis his team conducted to clarify the known associations.


Frenkel Coordination Exercises Demonstrate Reliability, Fatigue Benefits in Multiple Sclerosis

Frenkel Coordination Exercises Demonstrate Reliability, Fatigue Benefits in Multiple Sclerosis

February 25th 2021

The authors concluded that this approach may be applied in fatigue management treatment protocols, without increasing symptoms, in patients with multiple sclerosis.


Growing Multiple Sclerosis Treatment Knowledge: Luc Truyen, MD, PhD

Growing Multiple Sclerosis Treatment Knowledge: Luc Truyen, MD, PhD

February 25th 2021

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.


Cladribine Demonstrates CD19+ B and CD4+ T Lymphocyte Impact Regardless of Age

Cladribine Demonstrates CD19+ B and CD4+ T Lymphocyte Impact Regardless of Age

February 25th 2021

The effect of cladribine on CD8+ T lymphocytes varied by age, with steady increases shown in the younger population whereas there were fluctuations observed in the older group.


Measuring MS Fatigue in a Real-World Setting: Allitia DiBernardo, MD

Measuring MS Fatigue in a Real-World Setting: Allitia DiBernardo, MD

February 25th 2021

The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.

© 2025 MJH Life Sciences

All rights reserved.